Wolff-Parkinson-White syndrome drug prophylaxis: Difference between revisions
Jump to navigation
Jump to search
| Line 3: | Line 3: | ||
==Drug Prophylaxis In The Patient With Proven Tachyarrhythmias== | ==Drug Prophylaxis In The Patient With Proven Tachyarrhythmias== | ||
* Oral [[beta-blocker]], [[diltiazem]], and [[verapamil]] for prevention of [[AVRT]] in patients with out preexcitation in resting [[ECG]]. | * Oral [[beta-blocker]], [[diltiazem]], and [[verapamil]] for prevention of [[AVRT]] in patients with out preexcitation in resting [[ECG]]. | ||
* Oral [[flecainide]] and [[propaphenone]] in patients with preexcitation in resting [[ECG]] that are not candidates for catheter ablation and do not have structural or [[ischemic heart disease]] | * Oral [[flecainide]] and [[propaphenone]] in patients with preexcitation in resting [[ECG]] that are not candidates for catheter ablation and do not have structural or [[ischemic heart disease]].<ref name="PageJoglar2016">{{cite journal|last1=Page|first1=Richard L.|last2=Joglar|first2=José A.|last3=Caldwell|first3=Mary A.|last4=Calkins|first4=Hugh|last5=Conti|first5=Jamie B.|last6=Deal|first6=Barbara J.|last7=Estes III|first7=N.A. Mark|last8=Field|first8=Michael E.|last9=Goldberger|first9=Zachary D.|last10=Hammill|first10=Stephen C.|last11=Indik|first11=Julia H.|last12=Lindsay|first12=Bruce D.|last13=Olshansky|first13=Brian|last14=Russo|first14=Andrea M.|last15=Shen|first15=Win-Kuang|last16=Tracy|first16=Cynthia M.|last17=Al-Khatib|first17=Sana M.|title=2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia|journal=Heart Rhythm|volume=13|issue=4|year=2016|pages=e136–e221|issn=15475271|doi=10.1016/j.hrthm.2015.09.019}}</ref> | ||
==References== | ==References== | ||
Revision as of 12:38, 16 September 2020
|
Wolff-Parkinson-White syndrome Microchapters |
|
Differentiating Wolff-Parkinson-White syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Wolff-Parkinson-White syndrome drug prophylaxis On the Web |
|
Risk calculators and risk factors for Wolff-Parkinson-White syndrome drug prophylaxis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]
Drug Prophylaxis In The Patient With Proven Tachyarrhythmias
- Oral beta-blocker, diltiazem, and verapamil for prevention of AVRT in patients with out preexcitation in resting ECG.
- Oral flecainide and propaphenone in patients with preexcitation in resting ECG that are not candidates for catheter ablation and do not have structural or ischemic heart disease.[1]
References
- ↑ Page, Richard L.; Joglar, José A.; Caldwell, Mary A.; Calkins, Hugh; Conti, Jamie B.; Deal, Barbara J.; Estes III, N.A. Mark; Field, Michael E.; Goldberger, Zachary D.; Hammill, Stephen C.; Indik, Julia H.; Lindsay, Bruce D.; Olshansky, Brian; Russo, Andrea M.; Shen, Win-Kuang; Tracy, Cynthia M.; Al-Khatib, Sana M. (2016). "2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia". Heart Rhythm. 13 (4): e136–e221. doi:10.1016/j.hrthm.2015.09.019. ISSN 1547-5271.